Literature DB >> 3504244

Individual manifestations of Parkinson's disease after ten or more years of levodopa.

H L Klawans1.   

Abstract

Twenty-five consecutive patients with Parkinson's disease, who had been on levodopa for 10 or more years, were studied. Over the 12.9 years of treatment, the average Northwestern Disability Score had increased from 9.6 to 18.9. By this measure, 24 of 25 patients were worse, and one was unchanged. The progression of disability did not involve all pretreatment parkinsonian features equally in any of the patients studied. Instead a distinctive pattern of deterioration was seen: postural reflexes worsened in 24/25, speech in 24/25, and gait in 22/25. In contrast, rigidity was improved or unchanged in 17/25, tremor was improved or unchanged in 17/17, while handwriting was improved or unchanged in 21/22. Finger dexterity which was improved in 5/25, unchanged in 15/25, and worse in 5/25 which seemed to be between these two extremes. These observations demonstrate that some signs of parkinsonism can remain quite responsive to levodopa for more than 10 years while at the same time other manifestations of the disease are no longer as responsive to this form of treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3504244     DOI: 10.1002/mds.870010304

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

2.  Evolution of postural stability after subthalamic nucleus stimulation in Parkinson's disease: a combined clinical and posturometric study.

Authors:  D Guehl; P Dehail; M P de Sèze; E Cuny; P Faux; F Tison; M Barat; B Bioulac; P Burbaud
Journal:  Exp Brain Res       Date:  2005-11-19       Impact factor: 1.972

3.  Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders.

Authors:  R P Iacono; S M Kuniyoshi; J R Ahlman; G J Zimmerman; G Maeda; R D Pearlstein
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation.

Authors:  S Lubik; W Fogel; V Tronnier; M Krause; J König; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

5.  Disordered axial movement in Parkinson's disease.

Authors:  M J Steiger; P D Thompson; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

6.  Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.

Authors:  B P Bejjani; D Gervais; I Arnulf; S Papadopoulos; S Demeret; A M Bonnet; P Cornu; P Damier; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 7.  Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.

Authors:  Samuel D Kim; Natalie E Allen; Colleen G Canning; Victor S C Fung
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

8.  Square wave jerks in parkinsonian syndromes.

Authors:  O Rascol; U Sabatini; M Simonetta-Moreau; J L Montastruc; A Rascol; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-07       Impact factor: 10.154

9.  Age influences magnitude but not duration of response to levodopa.

Authors:  R Durso; K Isaac; L Perry; M Saint-Hilaire; R G Feldman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

10.  Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.

Authors:  L Rocchi; L Chiari; F B Horak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.